Hangzhou Diagens Biotechnology Co., Ltd./ADR
HGZDYDrugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Sep 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Picankibart
Psoriatic Arthritis
IBI112
Psoriasis
Capecitabine
Hepatocellular Carcinoma (HCC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Picankibart | Phase 3 | Psoriatic Arthritis | - | - |
IBI112 | Phase 3 | Psoriasis | - | - |
Capecitabine | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Hangzhou Diagens Biotechnology Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 3 drug candidates in Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) pipeline across Phase 3. Its lead program is Picankibart (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Hangzhou Diagens Biotechnology Co., Ltd./ADR's next FDA catalyst?→
Hangzhou Diagens Biotechnology Co., Ltd./ADR's (HGZDY) next tracked catalyst is a Phase 3 expected September 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track HGZDY biotech catalysts?→
Add HGZDY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Hangzhou Diagens Biotechnology Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.